What is the recommended methionine‑restricted diet protocol for patients with cystathionine β‑synthase deficiency, including protein limits, cystine supplementation, and monitoring?

Methionine-Restricted Diet for CBS Deficiency

For pyridoxine non-responsive patients with cystathionine β-synthase (CBS) deficiency, implement a methionine-restricted diet with cystine supplementation, aiming to keep plasma methionine below 80 μmol/L and total homocysteine below 100 μmol/L. 1, 2

Treatment Algorithm Based on Pyridoxine Responsiveness

Pyridoxine Non-Responders (Primary Dietary Management)

Dietary Protein Restriction:

• Restrict natural protein intake to achieve plasma methionine <80 μmol/L 3
• While some patients tolerate natural protein above WHO safe minimum, severe restriction is typically required 2
• Use methionine-free amino acid mixtures to meet total protein requirements 2

Critical Caveat: Estimates of methionine content in dietary proteins vary widely in the literature, making precise calculations challenging 2. Work closely with a metabolic dietitian experienced in CBS deficiency.

Cystine Supplementation:

• Mandatory supplementation since cysteine becomes an essential amino acid when the transsulfuration pathway is blocked 1
• Cystine (not cysteine) is the preferred form, as it serves as a superior substrate for alternative metabolic pathways 4

Adjunctive Pharmacotherapy

Betaine:

• Use as an adjunct to dietary control, not as an alternative 5
• Betaine remethylates homocysteine to methionine, which paradoxically increases methionine levels 1, 3
• Critical Warning: When plasma methionine exceeds 80 μmol/L, betaine becomes ineffective at lowering homocysteine, even at therapeutic serum betaine concentrations >250 μmol/L 3
• Dangerously high methionine levels (>3,000 μmol/L) on betaine therapy have caused massive cerebral edema 5
• Monitor methionine levels closely; if they exceed 350 μmol/L, methionine transamination products accumulate 6

Pyridoxine in Non-Responders:

• Contrary to guidelines, many non-responders receive pyridoxine, sometimes at dangerously high doses 2
• May still provide benefit as a cofactor in methionine metabolism even in non-responders 1
• Doses: 50-250 mg/day when used 1

Additional Cofactors:

• Folic acid: 0.4-5 mg/day 1
• Vitamin B12: 0.02-1 mg/day 1

Monitoring Parameters

Target Levels:

• Primary goal: Plasma total homocysteine <100 μmol/L 2
• Optimal: Plasma methionine <80 μmol/L when using betaine 3
• Warning threshold: Methionine >350 μmol/L triggers transamination pathway activation 6

Frequency:

• Regular monitoring of plasma methionine, homocysteine, and betaine levels
• More frequent monitoring when adjusting betaine doses or dietary protein intake

Clinical Outcomes

Evidence of Effectiveness: Early treatment in newborn-screened patients dramatically reduces complications compared to clinically detected cases 2:

• Thromboembolism risk reduction: 93% (risk ratio 0.073)
• Lens dislocation risk reduction: 93% (risk ratio 0.069)

Common Pitfall: High homocysteine levels despite appropriate prescriptions often reflect poor compliance rather than treatment failure 2. The registry data showed similar homocysteine concentrations across groups prescribed high or low betaine doses and varying natural protein intakes, suggesting adherence is the limiting factor.

Practical Implementation

1. Start with strict dietary methionine restriction using methionine-free amino acid mixtures
2. Add cystine supplementation immediately
3. Consider betaine cautiously only after dietary control is established
4. Monitor methionine levels closely - if rising above 80 μmol/L, tighten dietary restriction before increasing betaine
5. Continue pyridoxine and B-vitamin cofactors even in non-responders
6. Maintain lifelong treatment - late complications occur even in adults 7

The key principle is that dietary control must be the foundation, with betaine serving only as an adjunct when methionine levels are controlled 5.